2018 Publications

Should the 6-Minute Walk Test Be Stopped If Oxyhemoglobin Saturation Falls Below 80%? View Article. 2018. Afzal S., Burge A.T., Lee A.L., Bondarenko J., Holland A.E. Archives of Physical Medicine and Rehabilitation 99(11).

An alternative approach to the current diagnostic guidelines for fibrotic interstitial lung disease. View Article. 2018. Moodley Y. Respirology 23(6).

A standardized diagnostic ontology for fibrotic interstitial lung disease. View Article. 2018. Moodley Y. American Journal of Respiratory and Critical Care Medicine 197(10).

Telerehabilitation versus traditional centre-based pulmonary rehabilitation for people with chronic respiratory disease: Protocol for a randomised controlled trial. View Article. 2018. Cox N.S., McDonald C.F., Alison J.A., (…) Holland A.E. BMC Pulmonary Medicine 18(1).

Multimorbidity rehabilitation versus disease-specific rehabilitation in people with chronic diseases: A pilot randomized controlled trial. View Article. 2018. Barker K., Holland A.E., Lee A.L., Haines T., Ritchie K., Boote C., Saliba J., Lowe S., Pazsa F., Thomas L., Turczyniak M., Skinner E.H. Pilot and Feasibility Studies 4(1).

Composite physiologic index in Idiopathic Pulmonary Fibrosis: Effects of nintedanib. View Article. 2018. Glaspole I, Wells A, Behr J, Stansen W, Stowasser S, Maher T. Respirology 23:125.

The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. View Article. 2018. Schuliga M., Grainge C., Westall G., Knight D. International Journal of Biochemistry and Cell Biology 97.

Cyclophosphamide for connective tissue disease-associated interstitial lung disease. View Article. 2018. Barnes H., Holland A.E., Westall G.P., Goh N.S.L., Glaspole I.N. Cochrane Database of Systematic Reviews. 1.

Cyclophosphamide for connective tissue disease-associated interstitial lung disease. View Article. 2018. Barnes H, Goh N, Westall G, Holland A, Glaspole I. Respirology. 23:124.

Occupational and environmental risk factors for Idiopathic Pulmonary Fibrosis in Australia. View Article. 2018. Abramson, MJ, Murumbadoro T, Alif SM, Benke G et al. European Respiratory Journal. 52. doi: 10.1183/13993003.congress-2018.PA5068.

Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts. View Article. 2018. Schuliga, M., Pechkovsky, D. V., Read, J., Waters, D. W., Blokland, K.E. C., Reid, A. T., (…) Knight, D. A. Journal of Cellular and Molecular Medicine, 22(12), 5847-5861.

Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. View Article. 2018. Waters DW, Blokland KEC, Pathinayake PS, Burgess JK, Mutsaers SE, Prele CM, Schuliga M, Grainge CL, Knight DA. American Journal of Physiology-Lung Cellular and Molecular Physiology. doi: 10.1152/ajplung.00037.2018.

Idiopathic Pulmonary Fibrosis. View Article. 2018. Jo HE and Corte TJ. Australian Doctor 6 April; 17-24. https://www.howtotreat.com.au/node/47341/1.

Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis. View Article. 2018. Griffiths K, Habiel DM, Jaffar J, Binder U, Darby WG, Hosking CG, Skerra A, Westall GP, Hogaboam CM, Foley M.  Scientific Reports. 8: 3212. doi: 10.1038/s41598-018-20811-5.

Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. View Article. 2018. Koutsakos M, (…) Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO, Kedzierska K. American Association for the Advancement of Science. 10, 428. doi: 10.1126/scitranslmed.aan8405.

Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. View Article. 2018. Pizzolla A, Nguyen TH, Sant S, Jaffar J, Loudovaris T, Mannering SI, Thomas PG, Westall GP, Kedzierska K, Wakim LM. Journal of Clinical Investigations 128 (2):721-733.

Safe and effective exercise training for patients with pulmonary arterial hypertension: putting current evidence into clinical practice. View Article. 2018. Lavender M, Chia KS, Dwyer N, Corte TJ, Spencer L, Thakkar V, McWilliams T, Kotlyar E, Whitford H. Expert Review of Respiratory Medicine. 12(11):965-977. doi: 10.1080/17476348.2018.1527687.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. View Article. 2018. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V. BMJ Open Respiratory Research. 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. 

Should Patients With Interstitial Lung Disease Be Seen by Experts? View Article. 2018. Cottin V, Castillo D, Poletti V, Kreuter M, Corte TJ, Spagnolo P. Chest. 154(3):713-714. doi: 10.1016/j.chest.2018.05.044.

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. View Article. 2018. Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, (…) Ryerson CJ. Respiration. 96(4):314-322. doi: 10.1159/000489668. 

Greater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis. View Article. 2018. Jaffar J, Yang SH, Kim SY, Kim HW, Faiz A, Chrzanowski W, Burgess JK.American Journal of Physiology-Lung Cellular and Molecular Physiology. doi: 10.1152/ajplung.00030.2018

New treatment paradigms for connective tissue disease-associated interstitial lung disease. View Article. 2018. Kouranos V, Miranda G, Corte TJ, Renzoni EA. Current Opinion Pulmonary Medicine. 24(5):453-460. doi: 10.1097/MCP.0000000000000508

Casein kinase δ/ε inhibitor, PF670462 attenuates the fibrogenic effects of Transforming Growth Factor-β in pulmonary fibrosis. View Article. 2018. Stewart AG, Keenan C, Langenbach S, Jativa F, Harris T, Schuliga M, Jaffar J, Westall GP, Berhan A, Prodanovic D, Lee PV, Tu Y. Frontiers in Pharmacology (9):738. doi:10.3389/fphar.2018.00738

Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. View Article. 2018. Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, (…) Corte TJ. Medical Journal of Australia. 208(2):82-88. doi: 10.5694/mja17.00799.

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. View Article. 2018. Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ. BMC Pulmonary Medicine. 18(1):19. doi: 10.1186/s12890-018-0575-y.

Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. View Article. 2018. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators. American Journal of Respiratory and Critical Care Medicine. 197(8):1036-1044. doi: 10.1164/rccm.201710-1986OC.

Short and long term reliability of the 6-minute walk test in people with idiopathic pulmonary fibrosis. View Article. 2018. Holland AE, Hill CJ, Dowman L, Glaspole I, Goh N, Lee AL, McDonald CF. Respiratory Care. 63(8):994-1001.

How do new molecular tools apply to my clinical practice? View Article. 2018. Yang I.A., Moodley Y. Respirology 23(11).

Autophagy and the unfolded protein response promote profibrotic effects of TGF-β1 in human lung fibroblasts. View Article. 2018. Ghavami S., Yeganeh B., Zeki A.A., Shojaei S., Kenyon N.J., Ott S., Samali A., Patterson J., Alizadeh J., Moghadam A.R., Dixon I.M.C., Unruh H., Knight D.A., Post M., Klonisch T., Halayko A.J. American Journal of Physiology – Lung Cellular and Molecular Physiology 314(3).

A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. View Article. 2018. Parker J.M., Glaspole I.N., Lancaster L.H., Haddad T.J., She D., Roseti S.L., Fiening J.P., Grant E.P., Kell C.M., Flaherty K.R. American Journal of Respiratory and Critical Care Medicine 197(1).

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. View Article. 2018. Kolb M, Raghu G, Wells A, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez F for the INSTAGE Investigators New England Medical Journal 379 (18).